CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma

The alkylating agent, temozolomide (TMZ), is the most commonly used chemotherapeutic for the treatment of glioblastoma (GBM). The anti-glioma effect of TMZ involves a complex response that includes G2-M cell cycle arrest and cyclin-dependent kinase 1 (CDK1) activation. While CDK1 phosphorylation is...

Descripción completa

Detalles Bibliográficos
Autores principales: Voce, David J., Bernal, Giovanna M., Cahill, Kirk E., Wu, Longtao, Mansour, Nassir, Crawley, Clayton D., Campbell, Paige-Ashley S., Arina, Ainhoa, Weichselbaum, Ralph R., Yamini, Bakhtiar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952566/
https://www.ncbi.nlm.nih.gov/pubmed/33707466
http://dx.doi.org/10.1038/s41598-021-84912-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952566/
https://www.ncbi.nlm.nih.gov/pubmed/33707466
http://dx.doi.org/10.1038/s41598-021-84912-4

Ejemplares similares